News for Immunocore Holdings plc (IMCR)

Immunocore Holdings (IMCR) has been the focus of recent attention as H.C. Wainwright & Co. analyst Patrick Trucchio reiterated their "Buy" rating on the stock.

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, June 2, 2025) Immunocore Holdings plc ( IMCR) (”œImmunocore” or the ”œCompany”), a co

Deutsche Bank has begun coverage of Immunocore, assigning the stock (IMCR) a Buy rating and setting a price target of $65. The bank highlights the success of Ki

Revenue: Achieved $93.9 million in Q1 2025, surpassing the estimated $88.52 million, marking a 33% year-over-year growth.Earnings Per Share (EPS): Reported EPS

Immunocore (IMCR) reported first-quarter revenue of $93.9 million, exceeding the market forecast of $86.45 million. This represents a substantial year-over-year

**media[617235]**

Immunocore Holdings' stock has dropped 60% as Kimmtrak faces market saturation, but its pipeline could offer potential. Find out why IMCR stock is a hold.

On March 17, 2025, Baker Bros. Advisors LP executed a significant transaction involving Immunocore Holdings PLC. The firm added 807,338 shares to its holdings,

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 IMC-M113V was well tolerated, w

**media[562440]**

Immunocore Holdings PLC (IMCR), a commercial-stage biotechnology company known for its pioneering work in immunomodulating medicines, announced on March 3, 2025

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 03 March 2025) Immunocore Holdings plc ( IMCR) (”œImmunocore” or the ”œCompany”), a c

Immunocore Holdings PLC's innovative ImmTAX platform positions it as a leader in TCR bispecific immunotherapies.Commercial success of KIMMTRAK in multiple coun

IMCR's strong balance sheet, with over $800 million in liquid assets, positions them well for future R&D or even a potential acquisition. Read more about IMCR stock here.

Feb 26, 2025 / 01:00PM GMTOperator Greetings and welcome to the Immunocore conference call and webcast. (Operator Instructions) As a reminder, this conference i

Immunocore Holdings plc (NASDAQ:IMCR) Q4 2024 Earnings Conference Call February 26, 2024 8:00 AM ETCompany ParticipantsClayton Robertson - Head, IRBahija...

Revenue: Fourth quarter net sales of $84.1 million, slightly below the estimated revenue of $85.73 million.Annual Revenue: Total net sales for 2024 reached $31

KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle m

Immunocore Holdings PLC (IMCR) is set to release its Q4 2024 earnings on Feb 26, 2025. The consensus estimate for Q4 2024 revenue is $85.73 million, and the ear